Relating to the establishment of a grant program to fund the United States Food and Drug Administration's drug development trials with ibogaine for the purpose of securing the administration's approval as a medication for treatment of opioid use disorder, co-occurring substance use disorder, and any other neurological or mental health conditions for which ibogaine demonstrates efficacy.

Introduced

In Committee

Floor

Crossed Over

Passed

Enacted

Overview Bill text 2 Compare versions History 23 Sponsors

No summary has been published for this bill. The full text is on the Bill text tab.

Chamber: House
Introduced: Mar 4, 2025
Last action: May 12, 2025 — Laid on the table subject to call
Session: 89R
Momentum: 66 · High

PASSAGE PROBABILITY

1% Unlikely

Why this number

Stage base Floor Consideration — base rate 19%, measured from TX's completed sessions
Momentum +4 66/100 from the pace of recorded action
Time since last action -22 522 days quiet

A transparent scoring model over stage, momentum, recency, sponsorship and recorded votes — not a trained predictor. Treat it as a way to rank attention, not as a forecast.